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Abstract
Female transgenic mice that constitutively overexpress the transcription factor ATF3 in the basal epithelium of the
mammary gland develop mammary carcinomas with high frequency, but only if allowed to mate and raise pups early in life.
This transgenic mouse model system reproduces some features of human breast cancer in that about 20% of human breast
tumor specimens exhibit overexpression of ATF3 in the tumor cells. The ATF3-induced mouse tumors are phenotypically
similar to mammary tumors induced by overexpression of activating Wnt/b-catenin pathway genes. We now show that the
Wnt/b-catenin pathway is indeed activated in ATF3-induced tumors. b-catenin is transcriptionally up-regulated in the
tumors, and high levels of nuclear b-catenin are seen in tumor cells. A reporter gene for Wnt/b-catenin pathway activity,
TOPGAL, is up-regulated in the tumors and several downstream targets of Wnt signaling, including Ccnd1, Jun, Axin2 and
Dkk4, are also expressed at higher levels in ATF3-induced tumors compared to mammary glands of transgenic females.
Several positive-acting ligands for this pathway, including Wnt3, Wnt3a, Wnt7b, and Wnt5a, are significantly overexpressed
in tumor tissue, and mRNA for Wnt3 is about 5-fold more abundant in transgenic mammary tissue than in non-transgenic
mammary tissue. Two known transcriptional targets of ATF3, Snai1 and Snai2, are also overexpressed in the tumors, and
Snail and Slug proteins are found to be located primarily in the nuclei of tumor cells. In vitro knockdown of Atf3 expression
results in significant decreases in expression of Wnt7b, Tcf7, Snai2 and Jun, suggesting that these genes may be direct
transcriptional targets of ATF3 protein. By chromatin immunoprecipitation analysis, both ATF3 and JUN proteins appear to
bind to a particular subclass of AP-1 sites upstream of the transcriptional start sites of each of these genes.
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Introduction
The bZip transcription factor, ATF3, has for some time been
known to have the potential to both activate and repress
transcription in a context-dependent manner [1–5]. ATF3
homodimers appear to be repressors [5,6], whereas heterodimers
with Jun or JunB activate gene expression [3]. Although ATF3
expression has clearly been associated with the DNA damage
response and responses to other cellular stressors [2,7–10], its
exact role in these processes remains unclear. In some systems,
ATF3 appears to function in tumor suppressive pathways [11,12],
and in particular has recently been associated with induction of
apoptosis after treatments that induce lethal levels of DNA damage
[13].
On the other hand, ATF3 has been shown to be growth
stimulatory or anti-apoptotic in several systems [1,14–19]. Several
recent studies implicate ATF3 in tumorigenesis. In a transgenic
mouse model in which human ATF3 is expressed from the bovine
cytokeratin 5 promoter (BK5.ATF3), we reported spontaneous
development of oral tumors, including about a 70% incidence of
squamous cell carcinomas at 16 months of age [20]. We recently
demonstrated that in this same model, parous female transgenic
mice develop mammary tumors with squamous differentiation in
the first year of life with an incidence of about 67% [21]. Although
the transgene is expressed in the basal, myoepithelial compartment
of the mammary gland throughout development, mammary
tumors do not develop in virgin, transgenic females. Hai and
colleagues have demonstrated overexpression of the ATF3 protein
in a majority of human breast cancers [19], and we have found by
immunohistochemistry (IHC) that in about 20% of human breast
cancers ATF3 is found to be localized to the nuclei of the tumor
cells; in the remaining ATF3-positive breast cancers, expression is
primarily seen in stromal elements [21].
Phenotypically, mammary tumors induced in the BK5.ATF3
model resemble tumors and dysplastic lesions that have been
reported in several transgenic models in which components of the
Wnt/b-catenin pathway are overexpressed and the pathway is
thereby constitutively activated [22–28]. For example, mammary
tumors that arise in mice expressing a stabilized form of b-catenin
from the cytokeratin 14 promoter express differentiation markers
characteristic of both mammary epithelium, including cytokeratin
8, and epidermis, including cytokeratin 10 [28]. We have found
aberrant expression of cytokeratins 5 and 8 in most tumor cells in
the BK5.ATF3 model [21], as well as supra-basal expression of
cytokeratins 6 and 10 and several cytokeratins that are
characteristic of the inner root sheath of hair follicles. Interestingly,
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basal cell layer in the tumors [21]. In both types of models,
squamous metaplastic histopathology is seen, with the tendency to
form cyst-like structures with a core of keratinaceous material and
cell debris, surrounded by a multi-layered epithelium that exhibits
several features of squamous differentiation. These phenotypic
similarities suggested the possibility that the Wnt/b-catenin
pathway is somehow activated in ATF3-induced mammary
tumors, or alternatively that ATF3 is a downstream effector of
Wnt/b-catenin signaling. However, functional links between
ATF3 and Wnt/b-catenin signaling have not been described in
the literature.
The Wnt/b-catenin pathway is well known for its involvement
in colon carcinogenesis [29]. About 85% of both familial and
sporadic colon cancers involve mutations in the APC gene that lead
to activation of the Wnt/b-catenin pathway [30]. Wnt/b-catenin
signaling is absolutely required for mammary gland development,
and acts at several critical time periods during pre- and post-natal
development. Over the past decade, several epigenetic abnormal-
ities in Wnt pathway genes have also been identified in human
breast cancer. Promoter methylation of the APC gene has been
found in about 40% of breast cancer cases [31,32], and high levels
of promoter methylation for several Wnt-inhibitory genes in the
SFRP and DKK families in breast cancer have also been reported
[33,34].
The canonical pathway of Wnt/b-catenin signaling [35] begins
with the interaction of an extracellular Wnt family protein with a
transmembrane receptor of the Fz family; each of these gene
families have more than a dozen members in mouse and human.
This triggers formation of a complex with a second membrane co-
receptor, Lrp5 or Lrp6, phosphorylation of both receptors, and
binding of two cytoplasmic proteins, Disheveled and Axin, to the
complex. In the unstimulated cell, cytoplasmic b-catenin associates
with a so-called destruction complex, containing the proteins Axin,
APC and Gsk3. In this complex, b-catenin is specifically
phosphorylated by the kinase activity of Gsk3, which marks it
for subsequent ubiquitylation and degradation by the proteasome.
Following Wnt binding to the receptor, the destruction complex
becomes tethered to the membrane ligand/receptor complex
through Axin and loses its affinity for b-catenin, which then
accumulates in the cytoplasm and is transported to the nucleus.
Transcription factors of the Tcf/Lef1 family in the nucleus are
then converted from repressors to activators by replacement of a
repressive partner, Groucho, with the activating partner, b-
catenin, thus activating transcription of an array of genes that
constitute the downstream mediators of the pathway. In many
systems, the pathway can be activated by adding exogenous Wnt
protein, or by inhibiting the activity of Gsk3.
In the present study, we show that the Wnt/b-catenin pathway
is functionally activated in mammary tumors induced in the
BK5.ATF3 model. Initial probing of possible molecular links
between ATF3 expression and Wnt/b-catenin identified robust
up-regulation in ATF3-induced tumors of Wnt3, Wnt3a, Wnt10b
and Wnt7b, several activating ligands for the canonical pathway.
Results
b-catenin is overexpressed in and localizes to the nuclei
of BK5.ATF3 tumor cells
In a previous study, similarities were noted between the
histopathology of ATF3-induced mammary tumors and lesions
described in several transgenic models in which the Wnt/b-
catenin pathway is upregulated. Notably, expression of a stabilized
form of b-catenin in basal cells from the Krt14 promoter resulted
in squamous metaplastic lesions and carcinomas, similar to the
pathology seen in BK5.ATF3 mammary tumors [28]; similarities
in aberrant patterns of cytokeratin expression were also seen
between these two models. However, there is no precedent in the
literature for an effect of ATF3 on the Wnt/b-catenin pathway.
To determine whether Wnt/b-catenin signaling is affected in the
BK5.ATF3 mammary tumorigenesis model, we first used IHC to
analyze the distribution of b-catenin in mammary glands and in
ATF3-induced tumors. In the absence of Wnt/b-catenin pathway
activation, b-catenin is important in maintaining epithelial interce-
llular communication [35] and is therefore found in normal
mammary duct epithelial cells, typically showing a diffuse
cytoplasmic distribution or localization to the basolateral plasma
membrane in glands from either BK5.ATF3 transgenic (Figure 1A)
or non-transgenic (Figure 1B) animals. Even in glands from older,
parous females, where b-catenin staining was heavier (Figure 1C)
normal ducts did not exhibit evidence of nuclear localization of b-
catenin. In control sections with normal rabbit IgG substituted for
the anti-b-catenin antibody, epithelial cells did not stain
appreciably for b-catenin (Figure 1D). Nuclear localization of b-
catenin is characteristic of canonical Wnt b-catenin pathway
activation [35]. In ATF3-induced mammary tumors (Figure 1E,F),
overall expression of b-catenin appeared to be stronger than in
normal tissue, and clear localization to the nuclei of tumor cells
was widespread. Nuclear b-catenin was seen extensively in the
basal layers of the tumors (arrows, Figure 1E,F), but was also seen
in supra-basal cells (arrowheads, Figure 1E,F). In ten independent
tumors examined in detail, an average of 43% of tumor cells
exhibited clear nuclear expression of b-catenin. Nuclear labeling of
tumor cells was abolished when normal rabbit IgG was substituted
for the specific b-catenin antibody (Figure 1G).
To confirm this finding, mRNA was prepared from normal
mammary glands of young adult virgin females, ATF3-induced
mammary tumors, and MMTV.neu-induced mammary tumors,
and analyzed by quantitative polymerase chain reaction (qPCR).
b-catenin mRNA was detected at similar levels in normal
mammary tissue from non-transgenic mice and BK5.ATF3
heterozygous mice (Figure 2A). Seven independent ATF3-induced
tumors exhibited an average of about three-fold higher levels of b-
catenin mRNA as compared to normal mammary glands from
BK5.ATF3 animals (t-test, p,.001). As expected, MMTV.neu
induced tumors [36] had no such increase in b-catenin mRNA
(p..05).
Downstream Wnt/b-catenin target genes are up-
regulated in BK5.ATF3 tumors
To determine whether the nuclear localization of b-catenin
correlated with activation of the Wnt/b-catenin pathway, we
utilized a reporter strain of mice, TOPGAL [37], in which Wnt/
b-catenin signaling drives the expression of a bacterial b-
galactosidase gene in a non-tissue-specific manner. Doubly
transgenic BK5.ATF3
Tg/0;TOPGAL
Tg/0 female mice, hemizygous
for both transgenes, were allowed to raise two litters of pups, and
then monitored for mammary tumor formation until 16 months of
age. As expected, about two-thirds of these mice developed
mammary tumors between the ages of 6 and 12 months. Indeed,
the survival of these mice (Figure S1A) was virtually identical to that
reported for singly transgenic BK5.ATF3 mice, and the histopa-
thology of the resulting tumors (Figure S1B) was also unchanged by
the TOPGAL transgene. By qPCR, expression of the b-galactosi-
dase transgene was increased an average of about 7-fold in tumors
producedindoublytransgenicmice comparedtonormalmammary
glands of TOPGAL mice (Figure 2A; p,0.01). There was no
significant difference in b-galactosidase expression between normal
Wnt/b-Catenin Pathway Activation by ATF3
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BK5.ATF3 transgene (p.0.05). These findings strongly indicate
that the Wnt/b-catenin pathway is activated in these tumors, but
not in normal mammary glands of BK5.ATF3 transgenic mice.
Analysis of bacterial b-galactosidase expression by IHC was
complicated by background cross-reactivity in ATF3-tumors
induced in non-TOPGAL mice (Figure 3A). It can be seen that
modest but fairly uniform staining was seen in the supra-basal
tumor cells (arrows) but not in the basal cell layer of the tumors
(asterisks). The antibody used for IHC is known to cross-react with
mouse b-galactosidase, suggesting that the mouse protein may be
present in the supra-basal layers of these tumors. In contrast,
Figure 1. IHC analysis of b-catenin in ATF3-induced mammary tumors. b-catenin expression was assessed by immunohistochemistry in
normal mammary glands of: A, young (18 weeks), non-parous BK5.ATF3 females; B, young (18 weeks), non-parous non-transgenic females; or C,D,
older parous non-transgenic females; in panel D, non-specific rabbit IgG was substituted for the anti- b-catenin antibody as a negative control.
Mammary tumors derived from parous BK5.ATF3 females were analyzed with the anti- b-catenin antibody (panels E, F), or with the IgG control (panel
G). Arrows in panels E and F indicate typical nuclear staining of basal tumor cells, and arrowheads indicate supra-basal nuclei. Scale bar in G=50mm,
applies to all panels.
doi:10.1371/journal.pone.0016515.g001
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Tg/0;TOPGAL
Tg/0 mice (Figure 3B)
demonstrated uniform staining throughout both the basal and
supra-basal layers of the tumor. We conclude that activation of the
Wnt/b-catenin pathway occurs at least in the basal cell layers of
these tumors, coincident with nuclear expression of ATF3 [21].
As a further test of Wnt/b-catenin pathway activation, we used
qPCR and protein immunoblotting to monitor activity of known
downstream transcriptional targets of this pathway. Wnt/b-
catenin signaling is usually associated with increased cell
proliferation, and correlated with this, Ccnd1 and Jun have both
been shown to be transcriptional targets of the Wnt/b-catenin
pathway [38–40]. As shown in Figure 2B, the Ccnd1 gene was up-
regulated about four-fold in ATF3-induced tumors compared to
normal mammary glands (p,0.001), and Jun expression was up
about two-fold (p,0.001). Furthermore, at the protein level,
robust up-regulation of both cyclin D1 and Jun proteins was seen
in immunoblots (Figure 2C). Interestingly, immunoprecipitation of
mammary tumor extracts with ATF3-specific antiserum, followed
by immunoblotting demonstrated significant intracellular associ-
ation between ATF3 and Jun proteins (Figure 2D). ATF3-Jun
Figure 2. Expression analysis of Wnt/b-catenin pathway genes. Gene expression analysis was performed as described in Materials and
Methods by quantitative real-time PCR for: A, Ctnnb1, bacterial b-galactosidase, Snai1; and B, Ccnd1, Jun, Axin2, and Dkk4. WT, mammary glands from
non-transgenic mice; TG, mammary glands from BK5.ATF3 mice; TU, mammary tumors from BK5. ATF3 mice; Neu, mammary tumors from MMTV.neu
mice. The mean and standard deviation of relative expression levels for at least 5 individual mice are shown; for all genes the mean expression level
obtained with BK5.ATF3 mammary glands was set to 1.0. The statistical significance of differences between mean expression levels, calculated relative
to BK5.ATF3 mammary glands, is indicated over the bars of the histograms: *, p,0.05; **, p,0.01; ***, p,0.001. C, immunoblots from a
representative BK5.ATF3 mammary gland extract (M) and a mammary tumor (T) are shown for Cyclin D1, Jun and Snail; laminin A,C is shown as a
protein loading control. D, extracts from paired mammary gland and tumor samples were immunoprecipitated with antibody to ATF3, then
electrophoresed and immunoblotted for ATF3 and Jun. E, immunoblots of nuclear extracts from non-transgenic mammary glands (lanes 1–3),
BK5.ATF3 transgenic mammary glands (lanes 4–6) or BK5.ATF3 mammary tumors (lanes 7–9) were prepared with a phospho-serine 73-Jun specific
antibody; all lanes are from a single representative gel.
doi:10.1371/journal.pone.0016515.g002
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of gene expression, whereas ATF3 homodimers are generally
thought to be repressors [3,5,6]. Jun must be phosphorylated at
serine 73 in order to exhibit maximal activity as a transcriptional
activator [41]. Using an antibody specific for phosphoserine-73,
we noted high but variable levels of phosphorylated Jun in extracts
from BK5.ATF3 transgenic mammary glands (Figure 2E, lanes 4–
6) and from BK5.ATF3-induced mammary tumors (Figure 2E,
lanes 7–9); much lower levels of activated Jun were seen in extracts
from non-transgenic mammary glands (Figure 2E, lanes 1–3).
Transcriptional activation of the Ccnd1 and Jun genes cannot be
taken to be absolutely specific for the Wnt/b-catenin pathway,
since both of these genes can be regulated by numerous other
factors. However, several genes that are involved in the negative
regulation of Wnt/b-catenin signaling, presumably as a homeo-
static mechanism, are also known to be direct transcriptional
targets of the pathway. Axin2, involved in negative regulation of
the b-catenin protein through destabilization, is one such pathway-
specific gene, known to be up-regulated by Wnt b-catenin
signaling [42]. As shown in Figure 2B, mRNA for Axin2 is
expressed at four-fold higher levels in ATF3-induced tumors as
compared to mammary glands (p,0.001). Dkk4, encoding a
soluble protein that binds to Wnt receptors in the plasma
membrane, but fails to activate downstream signaling, has also
been shown to be a direct transcriptional target of Wnt/b-catenin
pathway activation [43]. As shown in Figure 2B, Dkk4 mRNA is
barely detectable by qPCR in normal glands, but highly up-
regulated in ATF3-induced tumors (p,0.01); the increase is at
least 100-fold. In MMTV.neu mammary tumors in which the
Wnt/b-catenin pathway is not involved, expression of Axin2 was
extremely low (relative expression 0.01 compared to BK5.ATF3
mammary glands, p,0.01, data not shown), and Dkk4 was
undetectable. These data strongly suggest that Wnt/b-catenin
signaling is activated in BK5.ATF3 mammary tumors.
Wnt ligands are over-expressed in BK5.ATF3 tumors
Canonical activation of the Wnt/b-catenin pathway begins with
the binding of an activating Wnt protein to membrane receptors,
followed by downstream cytoplasmic events that lead to
stabilization of b-catenin, facilitating transport to the nucleus
and transcriptional activation of target genes. Several Wnt genes
that activate canonical Wnt signaling, including Wnt2, Wnt5a,
Wnt7b, and Wnt10b, are known to be expressed in the mammary
gland during ductal development [44,45]. Thus, one possible
mechanism for the activation of the Wnt b-catenin pathway by
ATF3 would be direct activation of transcription of one or more
Wnt genes. We analyzed the expression of 9 Wnt genes by qPCR in
mammary tumors derived from parous BK5.ATF3 mice, and in
normal, young adult mammary glands of non-transgenic and
transgenic mice (Table 1). Five Wnt genes were significantly
overexpressed in the tumors compared to transgenic mammary
glands, including Wnt3, Wnt3a, Wnt5a, Wnt7b and Wnt10b.
Notably, Wnt3 was up-regulated over 70-fold in ATF3-induced
tumors compared to transgenic mammary glands. Importantly,
the expression of Wnt3 was also 5-fold higher in transgenic glands
than in non-transgenic glands. This may reflect a role for Wnt3 in
the early stages of tumorigenesis in this model. None of the other
Wnt genes assayed exhibited significantly higher expression in
transgenic mammary glands compared to non-transgenic glands.
Two genes, Wnt1 and Wnt 5b, were significantly down-regulated in
ATF3-induced mammary tumors.
Snai1 and Snai2 are highly expressed in BK5.ATF3 tumors
The SNAI1 and SNAI2 genes have been implicated in tumor
progression and metastasis [46–49], and both were recently shown
to be direct transcriptional target of ATF3 in human mammary
cells [19]. The transcriptional repression activity of Snail and Slug
proteins [49] is expected to positively impact the canonical Wnt/
b-catenin pathway. However, the possible involvement of these
genes in the early phases of mammary tumorigenesis has not been
demonstrated. IHC analysis indicated robust expression of Snail
protein (the product of Snai1) in ATF3-induced mammary tumors
(Figure 4A). Nuclei of both basal and supra-basal epithelial tumor
cells (arrows and arrowheads, respectively) exhibited Snail
expression. In addition, scattered nuclei throughout the stroma
were strongly positive for Snail expression (dotted line). Nuclear
staining for Snail was not seen in control sections in which a
blocking peptide for Snail1 was included in the incubation
(Figure 4B). Scattered Snail-positive nuclei were observed in
normal mammary glands, in both the epithelial and stromal
compartments (Figure 4C). Essentially no expression of Snail was
seen in mammary tumors that developed in MMTV.neu
transgenic animals (Figure 4D). Further quantitative analysis of
five independent tumors indicated that 80–90% of tumor cell
nuclei were positive for Snail expression. Consistent with this,
qPCR analysis indicated about a four-fold up-regulation of Snai1
mRNA in these tumors compared to normal mammary glands in
BK5.ATF3 animals (Figure 2A, p,0.001). Slug (the protein
product of Snai2) was also expressed in the nuclei of tumor cells,
but in this case was seen primarily in the basal cell layers of the
tumors (Figure 4E). Quantitatively, only about 28% of the tumor
cells exhibited Slug expression; no staining was seen in normal
Figure 3. TOPGAL is expressed in ATF3-induced tumors. Immunohistochemistry was used to analyze expression of bacterial b-galactosidase
in mammary tumors from mice of genotype: A, BK5.ATF3
Tg/0;TOPGAL
0/0 or B, BK5.ATF3
Tg/0;TOPGAL
Tg/0. Arrows, supra-basal tumor cells; asterisks,
basal tumor cells.
doi:10.1371/journal.pone.0016515.g003
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exhibited Slug expression (Figure 4E, dotted line). qPCR analysis
of Snai2 expression failed to show a significant difference between
transgenic mammary glands and mammary tumors (data not
shown). This failure to detect increased levels of Snai2 mRNA may
be due to the restricted pattern of expression of Slug in basal
tumor cells only, as visualized by IHC.
Knock-down of ATF3 decreases expression of Wnt
pathway genes
Many of the changes in gene expression seen in ATF3-induced
mammary tumors may not be due to direct effects of ATF3 on the
transcription of the affected gene, but to indirect effects related to
changes in signaling pathways. We would like to know which, if
any, of the affected genes are direct targets of ATF3. As an initial
approach, we utilized in vitro transfection with siRNA to knock-
down Atf3 expression, and then measured the effects on the
expression of potential target genes. For these experiments, we
utilized a mouse mammary cancer cell line, EMT6, in which we
found robust expression of the endogenous Atf3 gene in
preliminary experiments. We identified three sequences from the
Atf3 mRNA that could potentially serve as targets for gene
silencing. As shown in Figure 5A, expression of ATF3 protein
could be knocked down in EMT6 cells by treatment with two
different siRNA sequences, A2 and A3, but not with a third siRNA
(A1). When assayed at the mRNA level by qPCR (Figure 5A), the
lowest dose of siRNAs A2 or A3 (0.5 nM) decreased the expression
level of the endogenous Atf3 mRNA by about 50% compared to
treatment with a scrambled version of siRNA A1, while higher
doses (1, 3, or 10 nM) gave ,90% knockdown.
In untreated EMT6 cells, we assayed expression of 15
endogenous mouse genes related to Wnt/b-catenin signaling
and/or previously identified as up-regulated in ATF3-induced
tumors. Expression of several genes of interest (Wnt3, Wnt3a and
Dkk4) was undetectable in these cells. However, six genes identified
as up-regulated in BK5.ATF3-induced tumors or transgenic
mammary glands were easily detected by qPCR (Jun, Snai1, Snai2,
Wnt7b, Wnt10b and Tcf7), and were chosen for further studies.
When Atf3 mRNA expression was knocked down by ,50% using
either siRNA A2 or A3, statistically significant 40–45% decreases
in the expression of both Snai2 and Wnt7b were seen (Figure 5B); in
all cases, decreases were calculated relative to treatment with a
scrambled siRNA that produced no knock-down of Atf3
expression. Expression of Tcf7 was similarly decreased by A3
under these conditions. On the other hand, expression of Wnt10b
was increased significantly by Atf3 knock-down with both A2 and
A3 (data not shown). With higher doses of siRNA A2, where Atf3
expression was knocked down .90%, about a 60% decrease in
Jun expression and a 35% decrease in Snai1 expression were also
seen (Figure 5B). SNAI1 and SNAI2, the human orthologues of
Snai1 and Snai2, have previously been shown to be direct
transcriptional targets of ATF3 [19], but transcriptional regulation
of the remaining genes by ATF3 has not been described.
As noted above for ATF3-expressing mammary glands, it is
possible that the high levels of expression of Atf3 and Jun in
untreated EMT6 cells promote formation of Atf3:Jun heterodi-
mers. Such heterodimers exhibit AP-1-like activity [3], activating
transcription through DNA binding sites with the consensus
sequence (A/G)TGA(G/C)T(C/A)A. For several genes that are
highly expressed in EMT6 cells (Jun, Tcf7, Snai2, Wnt7b and Snai1),
we noted the presence in the DNA sequence upstream of the
transcriptional start site of one (Jun, Snai2, Snai1) or two (Tcf7,
Wnt7b) close matches (Table 2) to a particular subclass of AP-1
sites (GTGA(G/C)TCA). As a preliminary test of whether binding
of ATF3 and/or JUN to these AP-1 sites might be involved in their
expression in EMT6 cells, we performed ChIP experiments
with antibodies against either ATF3 or JUN. For each of these
genes, PCR signals for the expected fragment(s) containing the
putative AP-1 binding site were obtained with chromatin preci-
pitated with either an ATF3-specific or a JUN-specific antibody
(Figure 6). The strongest PCR products in the ChIP experiment
were obtained for the putative AP-1 sites upstream of Jun (panel
A), Tcf7 (panels C,D) and Snai2 (panel E), for which the target
sequence exactly matched the GTGA(G/C)TCA motif (Table 2).
No PCR product was visible with either antibody in an assay
directed at a non-specific site upstream of Jun (panel B) that had no
match to this motif. The AP-1 sites upstream of Wnt7b and Snai1
contained one to three mismatches to the consensus motif
(Table 2), and the positive PCR signals obtained in the
corresponding ChIP samples (Figure 6, f–h) were somewhat
weaker. These results are consistent with the suggestion that Snai2,
Snai1, Tcf7, Jun and Wnt7b may be direct transcriptional targets of
ATF3 and JUN, possibly binding as a heterodimer to upstream
enhancer elements.
Table 1. Expression of Wnt genes in mammary glands and tumors.
Wnt Gene TG glands Relative Expression: Tumors
a Relative Expression: WT glands
Wnt3 1.060.4 73617*** 0.260.1*
Wnt3a 1.060.3 33.6612.3** 2.161.2
Wnt5a 1.060.6 7.26 1.6*** 1.360.5
Wnt7b 1.060.1 3.161.3** 2.060.9*
Wnt10b 1.060.5 2.460.4*** 0.960.4
Wnt4 1.060.1 1.660.5 1.260.8
Wnt9b 1.061.0 1.360.8 0.760.4
Wnt5b 1.060.6 0.260.1* 1.560.4
Wnt1 1.060.8 0.0360.01* 0.860.6
aAll data are expressed relative to the level of expression found in transgenic mammary glands. Statistical significance, determined by Student’s t-test, is indicated as
follows:
*, p,0.05;
**, p,0.01;
***, p,0.001.
doi:10.1371/journal.pone.0016515.t001
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In the present communication, we have provided several lines of
evidence that the canonical Wnt/b-catenin pathway is activated in
BK5.ATF3 mammary tumors. Characteristic overexpression of
the b-catenin protein and its appearance in nuclei of tumor cells is
seen. Downstream transcriptional targets, including Ccnd1, Jun,
Axin2 and Dkk4, are up-regulated, and a bacterial reporter gene
that is driven by Wnt/b-catenin signaling is activated in the
tumors. In addition, the genes for several positive-acting ligands
for the pathway, including Wnt3, Wnt3a, Wnt7b and Wnt10b, are
significantly over-expressed in tumors. Given the known impor-
tance of Wnt/b-catenin signaling in colorectal cancer [29,30], and
accumulating evidence suggesting that this pathway is often
dysregulated in human breast cancer [31–34,50,51], it seems likely
that Wnt/b-catenin signaling is important in the genesis of
mammary tumors in this mouse model. Experiments to test this
suggestion by blocking Wnt/b-catenin signaling in the transgenic
mice are in progress. This is consistent with results in several other
transgenic models [22–28] in which Wnt/b-catenin pathway
activation results in mammary tumors or preneoplastic lesions.
Several of these exhibit the tendency for squamous differentiation
that is extremely prominent within the ATF3-induced tumors.
There have been no previous reports linking ATF3 expression to
Wnt/b-catenin pathway activation. However, our finding that the
genes for several positive-acting Wnt ligands (Wnt3, Wnt3a, Wnt7b
and Wnt10b) are up-regulated in the tumors suggests the obvious
possibility that ATF3 may be acting as a direct transcriptional
regulator of one or more of these ligands. Consistent with this, we
find that knockdown of ATF3 expression in vitro reduces Wnt7b
expression and ChIP analysis in EMT6 cells suggests that both
AFT3 & JUN proteins bind to regions upstream of the Wnt7b
promoter that contain putative AP-1 consensus motifs. Other
positive ligands, particularly Wnt3 and Wnt3a which are highly up-
regulated in ATF3-induced tumors, may also be important in
tumorigenesis, but are expressed at very low levels in EMT6 cells
and therefore could not be tested in the knock-down experiments.
This model is attractive in that it provides an explanation for the
Figure 4. Snai1 and Snai2 are expressed in ATF3-induced tumors. Immunohistochemical analysis of Snail (coded by the Snai1 gene)
expression in: A,B, BK5.ATF3 mammary tumors; C, normal mammary gland of a non-transgenic female; D, a mammary tumor from a MMTV.neu
transgenic female. In panel B, a blocking peptide specific for Snail was incubated with the anti-Snail antibody as a negative control. Arrows, labeled
basal cell nuclei; arrowheads, labeled supra-basal cell nuclei. Immunohistochemical analysis of Slug (coded by the Snai2 gene) in E, a BK5.ATF3
mammary tumor and F, an apparently normal mammary gland from a tumor-bearing BK5.ATF3 female. Scale bar in E=50mm, applies to all panels.
doi:10.1371/journal.pone.0016515.g004
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b-catenin expression, while only basal cells over-express ATF3.
Because Wnt ligands are secreted and act extra-cellularly [35], both
autocrine and paracrine stimulation of the pathway in the basal and
supra-basal cells, respectively, might reasonably be expected to
occur, leading to the pattern of nuclear b-catenin expression seen.
Non-parous, BK5.ATF3 females do not develop mammary
tumors [21], and their mammary glands do not express high levels
of b-catenin mRNA (Figure 2B), do not exhibit nuclear locali-
zation of b-catenin (Figure 1A), and are unable to activate the
TOPGAL reporter gene (Figure 2A). Thus, although ATF3 is
clearly expressed throughout post-natal development in the basal
cell compartment of mammary glands in BK5.ATF3 transgenic
females, this overexpression by itself in not sufficient to produce
tumors, nor to fully activate the Wnt/b-catenin pathway. The
effects of ATF3 expression in other systems are strongly context-
dependent [3,19], and can include both apoptosis [13] and growth
stimulation [14–17], oncogenesis [18–21] and tumor suppression
[12]. The requirement for parity to induce mammary tumorigen-
esis in the current model suggests that during pregnancy, lactation
and/or involution contextual changes occur that allow full Wnt/
b-catenin pathway activation to occur. Preliminary histopatholog-
ical analyses (data not shown) have revealed that at mid-lactation,
lobulo-alveolar differentiation is incomplete in transgenic glands,
and further studies of this process and of involution at both the
histological and molecular levels are in progress.
The SNAI2 and SNAI1 genes have recently been identified as
direct transcriptional targets of ATF3 in human mammary cells
Figure 5. Decreases in gene expression following ATF3 knock-down in EMT6 cells. EMT6 cells were transfected with silencing RNAs A1, A2,
or A3 as described in Materials and Methods, or with a scrambled version of A1, at the indicated concentrations. A, 48 h later extracts were analyzed
for ATF3 protein expression by immunoblotting (upper panels) or for mRNA expression by qPCR (lower panel). Gene expression levels are expressed
relative to expression in cells treated with the scrambled siRNA. The statistical significance of differences between mean expression levels, calculated
relative to the scrambled siRNA control, is indicated over the bars of the histograms: *, p,0.05: **, p,0.01: ***, p,0.001. B, qPCR was used to analyze
the same extracts for Snai2, Wnt7b, Tcf7, Jun, and Snai1 as indicated. Black bars, scrambled siRNA; dark gray bars, 0.5 nmol A2siRNA; light gray bars,
0.5 nmol A3siRNA; white bars, 1–10 nmol A2siRNA.
doi:10.1371/journal.pone.0016515.g005
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in ATF3-induced mammary tumors (Figure 4). Multiple, bi-
directional interactions between Wnt/b-catenin pathway activa-
tion and Snail have been identified previously. Snail interacts
directly with nuclear b-catenin [52] and indirectly through
repression of E-cadherin [49] to increase the transactivation
capacity of b-catenin. Wnt pathway activation, on the other hand,
up-regulates Snail activity by stabilizing nuclear Snail protein in an
Axin2/GSK3b-mediated process [53]. Thus, a direct transcrip-
tional activation of Snail by ATF3 may also be important in
activating and/or maintaining Wnt/b-catenin signaling in these
tumors through a positive feedback loop.
Global gene expression analyses of human breast tumors have
identified an expression pattern consistent with up-regulation of the
canonical Wnt/b-catenin pathway that associates with the basal-like
tumor subclass [54,55]. Since there is significant overlap between the
basal-like subclass and clinically defined triple negative breast cancer
[56,57], this implies that Wnt/b-catenin signaling is important in
triple negative breast cancer, representing those breast cancers that
have the worst prognosis and no effective treatment regimen.
Importantly, Rosen’s laboratory has recently shown that activation of
Wnt/b-catenin signaling is a hallmark of tumor-initiating cells in a
mouse model [58]. Thus we have reason to believe that further
analysis of the BK5.ATF3 model, in which mammary tumors are
clearly basal-like and exhibit activated Wnt/b-catenin signaling, may
provide a better understanding of processes that are extremely
important in human breast tumorigenesis.
Materials and Methods
Detailed methods for IHC, protein immunoblotting, qPCR,
RNA silencing and ChIP analysis are given in Supplementary
Materials and Methods (Text S1).
Animals
Mice were maintained in a light and temperature controlled
room in an AAALAC-accredited facility, and given water and lab
chow ad libitum. All experimental procedures were approved by the
Institutional Animal Care and Use Committee of The University
of Texas MD Anderson Cancer Center under protocol #05-01-
03934. The derivation of the BK5.ATF3 transgenic mice has been
described [20]. TOPGAL mice and MMTV.neu mice were
obtained from Jackson Laboratory (Bar Harbor, ME). Genotyping
was done with appropriate PCR assays, using DNA purified from
tail snips.
A tumor experiment with female mice that were hemizygous for
both the BK5.ATF3 and TOPGAL transgenes was performed by
first allowing the mice to mate and raise pups twice before the age
of 6 months. Parous females were palpated twice weekly and were
euthanized when palpable tumors reached 1.5 cm in diameter or
when animals became moribund. The experiment was terminated
at 16 months.
Cell culture
The EMT6 line of murine mammary cancer cells (ATCC:
CRL-2755TM) was maintained in Waymouth’s MB 752/1
Figure 6. ChIP analysis of ATF3 and JUN binding to selected
AP-1 sites. Nuclei from untreated EMT6 cells were prepared for
chromatin immunoprecipitation as described in Materials and Methods,
and precipitated with antibodies specific for ATF3 or JUN, or with a non-
specific IgG. DNA was purified from the precipitates and used as
template in PCR reactions designed to amplify fragments containing
AP-1 sites at the indicated distances upstream of the murine genes for:
A, Jun; C,D, Tcf7; E, Snai2; F,G, Wnt7b; H, Snai1. In panel B, the PCR
targeted a non-specific site over 6000 bp upstream from the Jun
transcriptional start site that did not contain an AP-1 site. In each panel,
a small fraction of the starting DNA (2%) was used as template for the
reaction in the first lane (Input), and the remaining lanes used the
indicated immunoprecipitated DNA preparations (IgG, ATF3 and JUN).
doi:10.1371/journal.pone.0016515.g006
Table 2. Putative AP-1 sites.
Gene Position Sequence
Jun 24937 GTGACTCA
Tcf7 22677 GTGACTCA
Tcf7 23612 GTGACTCA
Snai2 24920 GTGACTCA
Wnt7b 2911 GTGAGaCA
Wnt7b 24828 GTGAtTaA
Snai1 21405 cTtAGTaA
doi:10.1371/journal.pone.0016515.t002
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5% CO2, and 37uC.
RNA purification and qPCR
Total RNA was isolated using TRIzol reagent (Invitrogen,
Grand Island, NY) according to the manufacturer’s protocol, and
reverse transcribed using the High Capacity cDNA Archive kit
(Applied Biosystems, Foster City, CA). Real-time PCR was
performed with an ABI Prism 7900HT Sequence Detection
System (Applied Biosystems). Student’s t-test (two-tailed, assuming
unequal variance) was used to determine statistical significance (p-
values) for differences in the relative expression values between
tissues for each gene analyzed. p-values less than 0.05 were
considered significant.
Supporting Information
Text S1 Supplementary Materials and Methods
(DOC)
Figure S1 Mammary tumorigenesis in parous
BK5.ATF3; TOPGAL mice. Singly transgenic animals from
the BK5.ATF3 line and the TOPGAL line were mated to produce
double heterozygotes (ATF3
+/2, TOPGAL
+/2). The doubly
heterozygous females and their singly transgenic (ATF3
2/2,
TOPGAL
+/2) littermates were allowed to mate and raise litters
twice, and then monitored for mammary tumor formation until 16
months of age. Tumor-bearing animals were sacrificed when a
tumor reached 1.5 cm in its longest dimension. A. Survival curves
are shown for several different genotypes. Data for TOPGAL non-
TG/ATF3 TG mice is from reference (Wang et al., 2008). B.
Tumors arising in (ATF3
+/2, TOPGAL
+/2) females were
harvested and analyzed by histopathology. Scale bar in panel
B=50mm.
(TIF)
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